Dechra Pharmaceuticals PLC (OTCMKTS:DCHPF) Short Interest Update

Dechra Pharmaceuticals PLC (OTCMKTS:DCHPF) was the recipient of a significant growth in short interest during the month of August. As of August 31st, there was short interest totalling 58,800 shares, a growth of 17.6% from the August 15th total of 50,000 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.

Dechra Pharmaceuticals Stock Performance

Shares of Dechra Pharmaceuticals stock opened at $47.32 on Tuesday. Dechra Pharmaceuticals has a 1 year low of $27.90 and a 1 year high of $47.40. The firm’s 50-day moving average is $46.61 and its 200 day moving average is $39.27.

Analyst Ratings Changes

Separately, Stifel Nicolaus cut Dechra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, June 27th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $4,000.00.

Dechra Pharmaceuticals Company Profile

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies.